| 胡烨进,邓 旭,周阿德,旷 驰,袁 力.膀胱尿路上皮癌组织CRMP2、NUSAP1、hMSH2表达与临床病理参数和预后的关系研究[J].现代生物医学进展英文版,2021,(1):178-183. |
| 膀胱尿路上皮癌组织CRMP2、NUSAP1、hMSH2表达与临床病理参数和预后的关系研究 |
| The Study of Relationship between CRMP2, NUSAP1 and hMSH2 Expression and Clinicopathological Parameters and Prognosis in Bladder Urothelial Carcinoma |
| Received:July 23, 2020 Revised:August 18, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.01.040 |
| 中文关键词: 膀胱尿路上皮癌 CRMP2 NUSAP1 hMSH2 病理参数 预后 |
| 英文关键词: Bladder urothelial carcinoma CRMP2 NUSAP1 hMSH2 Pathological parameters Prognosis |
| 基金项目:湖南省卫生计生委科研计划项目（C2017156） |
|
| Hits: 1037 |
| Download times: 612 |
| 中文摘要: |
| 摘要 目的：探讨膀胱尿路上皮癌组织坍塌反应调节蛋白2（CRMP2）、核仁和纺锤体相关蛋白l（NUSAP1）、人类错配修复基因2（hMSH2）表达与临床病理参数和预后的关系。方法：选取2018年2月至2020年3月我院收治的85例膀胱尿路上皮癌患者，比较手术切除的癌组织和癌旁粘膜组织中CRMP2、NUSAP1、hMSH2表达情况。比较不同病理参数癌组织中CRMP2、NUSAP1、hMSH2阳性表达率差异，分析CRMP2、NUSAP1、hMSH2与膀胱尿路上皮癌患者预后的关系。结果：与癌旁组织比较，膀胱尿路上皮癌患者癌组织中CRMP2、NUSAP1阳性表达率增高（P＜0.05），hMSH2降低（P＜0.05）。T2-T4、高级别肿瘤患者癌组织中CRMP2、NUSAP1阳性表达率高于Tis-T1、低级别肿瘤患者（P＜0.05），多发癌组织中CRMP2阳性表达率高于单发（P＜0.05），T2-T4癌组织中hMSH2阳性表达率低于Tis-T1（P＜0.05）。总生存率、无复发生存率、无进展生存率比较，CRMP2阳性表达者低于CRMP2阴性表达者（P＜0.05），hMSH2阴性表达者低于hMSH2阳性表达者（P＜0.05），NUSAP1阳性表达者无复发生存率、无进展生存率低于NUSAP1阴性表达者（P＜0.05）。Cox风险比例回归分析结果显示复发、进展、CRMP2阳性表达、NUSAP1阳性表达、hMSH2阴性表达是膀胱尿路上皮癌患者不良预后的危险因素（P＜0.05）。结论：CRMP2、NUSAP1阳性表达，hMSH2阴性表达与膀胱尿路上皮癌临床病理参数、复发转移以及不良预后有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between the collapse response mediator proteins 2 (CRMP2), nucleolar and spindle-associated protein l (NUSAP1) and human mismatch repair gene2 (hMSH2) expression and clinicopathological parameters and prognosis in bladder urothelial carcinoma. Methods: From February 2018 to March 2020, 85 patients with bladder urothelial carcinoma who were admitted to our hospital were selected, and the CRMP2, NUSAP1 and hMSH2 expressions in the surgically resected cancer tissues and para-cancer mucosal tissues were compared. The positive expression rates of CRMP2, NUSAP1 and hMSH2 in cancer tissues with different pathological parameters were compared, and the relationship between CRMP2, NUSAP1 and hMSH2 and the prognosis of patients with bladder uloepithelial carcinoma were analyzed. Results: Compared with the para-cancer tissues, the positive expression rates of CRMP2 and NUSAP1 in the carcinoma tissues of bladder uloepithelial carcinoma patients were increased (P<0.05), while hMSH2 was decreased (P<0.05). The positive expression rates of CRMP2 and NUSAP1 in the cancer tissues of patients with T2-T4 and high-grade tumors were higher than those of Tis-T1 and low-grade tumors (P＜0.05), the positive expression rate of CRMP2 in multiple cancer tissues was higher than that of single cancer (P＜0.05), and the positive expression rate of hMSH2 in T2-T4 cancer tissues was lower than that of Tis-T1 (P＜0.05). In comparison of overall survival rate, relapse-free survival rate and progression-free survival rate, patients with CRMP2 positive expression was lower than patients with CRMP2 negative expression (P<0.05), and patients with hMSH2 negative expression was lower than patients with hMSH2 positive expression (P<0.05). The relapse-free and progression-free survival rate of patients with NUSAP1 positive expression was lower than those of patients with NUSAP1 negative expression (P<0.05). Coxproportional hazard regression analysis showed that recurrence, progress, CRMP2 positive expression, NUSAP1 positive expression and hMSH2 negative expression were risk factors for poor prognosis in bladder urothelial carcinoma (P<0.05). Conclusion: CRMP2, NUSAP1 positive expression, and hMSH2 negative expression are related to clinicopathological parameters, recurrence and metastasis and poor prognosis of bladder urothelial carcinoma. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
